Navigation Links
Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis

SPARTANBURG, S.C., Aug. 16, 2011 /PRNewswire/ -- Femasys Inc. and Norgenix Pharmaceuticals, LLC today announced an agreement for exclusive distribution rights in the United States as well as US territories and military bases for Femasys' FemVue™ Saline-Air Device. This FDA cleared device is used to evaluate a woman's fallopian tubes with standard ultrasound, called a Sono HSG. Femasys Inc. is an emerging medical device developer of women's healthcare solutions. Norgenix Pharmaceuticals, LLC, a wholly owned subsidiary of the J M Smith Corporation, is a North American distributor with a world-class sales channel for medical device and pharmaceutical products in the women's health arena. Norgenix is licensed to sell, market, and distribute medical devices and prescription drug products in all 50 US states.

"Our agreement with Norgenix is anticipated to have an immediate and significant impact on our sales expansion efforts as we offer the market an advancement in diagnostic care for an infertile woman," stated Kathy Lee-Sepsick, President & CEO of Femasys Inc. "The Norgenix team is providing us with multiple ready-made relationships; we are excited to ramp our production to meet the numerous opportunities Norgenix has presented."

The FemVue™ Saline-Air Device has been cleared by the FDA for use during diagnostic Sono HSG for fallopian tube evaluations. It creates a consistent alternating pattern of saline and air used as contrast allowing physicians to evaluate a woman's fallopian tubes with existing ultrasound equipment. With the FemVue pattern of saline and air, Sono HSG can be a reliable, cost-effective, convenient, and safe procedure performed quickly by a woman's gynecologist or infertility specialist in the office.

"We are pleased to announce our partnership with Femasys," stated Ken Couch, President of Norgenix Pharmaceuticals, LLC. "Femasys' FemVue device is an innovative product that perfectly aligns with our strategic mission to offer solutions to unmet needs in women's health."

"FemVue is an innovative solution in providing convenient and reliable evaluation of the fallopian tubes to the estimated 10 million women in the United States today, including those struggling with infertility or suffering from female fallopian tube disorders," stated Michael Rackley, COO & Senior Vice President of Norgenix Pharmaceuticals. "We are very optimistic about the potential for FemVue; we expect to expand the market rapidly."



Media Contact:
Sims Hammond, 864.580.2350,

SOURCE Norgenix Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Concord Medical Announces Higher Revenues, Net income, and Earnings per ADS for the Second Quarter 2011
2. Beacon Enterprise Solutions Announces $3.4 Million Contract Award With the Veterans Administration
3. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
4. 3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results
5. NewCardio Announces Financial Results for Its 2011 Second Quarter
6. Dehaier Medical Announces Record Second Quarter 2011 Financial Results
7. Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach
8. Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
9. GeoVax Labs, Inc. Announces Second Quarter Financial Results
10. Global Pharm Holdings Group, Inc. Announces Second Quarter 2011 Financial Results
11. Spherix Announces Second Quarter Financial Results
Post Your Comments:
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):